JP2019515042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515042A5 JP2019515042A5 JP2019510574A JP2019510574A JP2019515042A5 JP 2019515042 A5 JP2019515042 A5 JP 2019515042A5 JP 2019510574 A JP2019510574 A JP 2019510574A JP 2019510574 A JP2019510574 A JP 2019510574A JP 2019515042 A5 JP2019515042 A5 JP 2019515042A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- alkyl
- compound
- independently
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021067440A JP2021107415A (ja) | 2016-05-05 | 2021-04-13 | 統合ストレス経路のモジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332284P | 2016-05-05 | 2016-05-05 | |
| US62/332,284 | 2016-05-05 | ||
| PCT/US2017/031352 WO2017193030A1 (en) | 2016-05-05 | 2017-05-05 | Modulators of the integrated stress pathway |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021067440A Division JP2021107415A (ja) | 2016-05-05 | 2021-04-13 | 統合ストレス経路のモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515042A JP2019515042A (ja) | 2019-06-06 |
| JP2019515042A5 true JP2019515042A5 (https=) | 2020-06-25 |
| JP6869331B2 JP6869331B2 (ja) | 2021-05-12 |
Family
ID=58710114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510574A Expired - Fee Related JP6869331B2 (ja) | 2016-05-05 | 2017-05-05 | 統合ストレス経路のモジュレーター |
| JP2021067440A Pending JP2021107415A (ja) | 2016-05-05 | 2021-04-13 | 統合ストレス経路のモジュレーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021067440A Pending JP2021107415A (ja) | 2016-05-05 | 2021-04-13 | 統合ストレス経路のモジュレーター |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10864196B2 (https=) |
| EP (2) | EP3778575A1 (https=) |
| JP (2) | JP6869331B2 (https=) |
| CN (1) | CN109641853A (https=) |
| AR (1) | AR108394A1 (https=) |
| AU (1) | AU2017260363B2 (https=) |
| CA (1) | CA3023161A1 (https=) |
| ES (1) | ES2821790T3 (https=) |
| PT (1) | PT3452454T (https=) |
| TW (1) | TW201808914A (https=) |
| UY (1) | UY37231A (https=) |
| WO (1) | WO2017193030A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| CN108809583B (zh) | 2017-05-05 | 2024-03-26 | 华为技术有限公司 | 传输信号的方法和装置 |
| US11242327B2 (en) * | 2017-05-15 | 2022-02-08 | Recurium Ip Holdings, Llc | Analgesic compounds |
| CN110730777A (zh) * | 2017-06-07 | 2020-01-24 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4通路抑制剂的化学化合物 |
| WO2018225093A1 (en) * | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| CN118239937A (zh) * | 2017-08-09 | 2024-06-25 | 戴纳立制药公司 | 化合物、组合物及方法 |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| US11939320B2 (en) | 2017-11-02 | 2024-03-26 | Abbvie Inc. | Modulators of the integrated stress pathway |
| EP3704096B1 (en) * | 2017-11-02 | 2026-04-22 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| SG11202004009TA (en) * | 2017-11-02 | 2020-05-28 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| EP3704098B1 (en) * | 2017-11-02 | 2024-01-24 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| WO2019118785A2 (en) | 2017-12-13 | 2019-06-20 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| WO2019183589A1 (en) * | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019236710A1 (en) | 2018-06-05 | 2019-12-12 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| CA3112326A1 (en) | 2018-09-12 | 2020-03-19 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
| TWI877863B (zh) | 2018-10-11 | 2025-03-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| US12091392B2 (en) | 2019-02-13 | 2024-09-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| MA54953A (fr) * | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| MX2021012904A (es) * | 2019-04-23 | 2022-01-18 | Evotec Int Gmbh | Moduladores de la via de respuesta al estres integrada. |
| CA3137213A1 (en) | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| MX2021013197A (es) | 2019-04-30 | 2022-02-24 | Calico Life Sciences Llc | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. |
| JP2022536663A (ja) | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路のモジュレーター |
| AU2020321955A1 (en) | 2019-07-30 | 2022-03-17 | Eikonizo Therapapeutics, Inc. | HDAC6 inhibitors and uses thereof |
| KR20250127350A (ko) | 2019-09-26 | 2025-08-26 | 노파르티스 아게 | 항바이러스성 피라졸로피리디논 화합물 |
| IL326597A (en) | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic M1 acetylcholine receptor antagonists |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| MX2022007376A (es) | 2019-12-20 | 2022-09-02 | Tenaya Therapeutics Inc | Fluoroalqull-oxadiazoles y sus usos. |
| AU2021213289A1 (en) | 2020-01-28 | 2022-07-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| MX2022011143A (es) | 2020-03-11 | 2022-10-13 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| MX2023004623A (es) | 2020-10-22 | 2023-05-12 | Evotec Int Gmbh | Moduladores de la via integrada de respuesta al estres. |
| JP2023546224A (ja) | 2020-10-22 | 2023-11-01 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合ストレス応答経路のモジュレーター |
| US20230391763A1 (en) | 2020-10-22 | 2023-12-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| US20240252502A1 (en) | 2021-05-04 | 2024-08-01 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for treatment of metabolic disease and hfpef |
| TW202345813A (zh) | 2022-04-08 | 2023-12-01 | 美商艾科尼佐療法股份有限公司 | 㗁二唑ｈｄａｃ６抑制劑及其用途 |
| WO2024109736A1 (zh) * | 2022-11-21 | 2024-05-30 | 深圳众格生物科技有限公司 | 一种化合物、包含其的药物组合物及其合成方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212A (en) | 1847-07-31 | Richard m | ||
| US162A (en) | 1837-04-17 | Island | ||
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| CN101475538A (zh) * | 2002-12-20 | 2009-07-08 | 默克公司 | 用作11-β-羟基类固醇脱氢酶-1抑制剂的三唑衍生物 |
| EP1706384A1 (en) | 2004-01-07 | 2006-10-04 | AstraZeneca AB | Therapeutic agents i |
| CN101142172A (zh) | 2005-01-05 | 2008-03-12 | 艾博特公司 | 11-β-羟甾类脱氢酶1型酶的抑制剂 |
| JP2009504624A (ja) | 2005-08-08 | 2009-02-05 | アージェンタ ディスカバリー リミテッド | ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用 |
| JP5301999B2 (ja) * | 2005-10-31 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｃｅｔｐ阻害薬 |
| WO2011087758A1 (en) | 2009-12-22 | 2011-07-21 | H. Lundbeck A/S | Adamantyl amide derivatives and uses of same |
| AR084457A1 (es) | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | Derivados de biciclo[3,2,1]octilamida |
| JP6806562B2 (ja) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| US20160318856A1 (en) * | 2013-09-11 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Substituted Urea eIF2alpha Kinase Activators |
| CN109641910A (zh) * | 2016-06-24 | 2019-04-16 | 梅尔莎纳医疗公司 | 吡咯并苯二氮*及其缀合物 |
-
2017
- 2017-05-04 TW TW106114862A patent/TW201808914A/zh unknown
- 2017-05-05 AR ARP170101182A patent/AR108394A1/es unknown
- 2017-05-05 ES ES17724205T patent/ES2821790T3/es active Active
- 2017-05-05 CA CA3023161A patent/CA3023161A1/en not_active Abandoned
- 2017-05-05 CN CN201780042067.3A patent/CN109641853A/zh active Pending
- 2017-05-05 EP EP20184319.0A patent/EP3778575A1/en not_active Withdrawn
- 2017-05-05 US US16/098,950 patent/US10864196B2/en active Active
- 2017-05-05 JP JP2019510574A patent/JP6869331B2/ja not_active Expired - Fee Related
- 2017-05-05 AU AU2017260363A patent/AU2017260363B2/en not_active Expired - Fee Related
- 2017-05-05 PT PT177242054T patent/PT3452454T/pt unknown
- 2017-05-05 UY UY0001037231A patent/UY37231A/es not_active Application Discontinuation
- 2017-05-05 EP EP17724205.4A patent/EP3452454B1/en active Active
- 2017-05-05 WO PCT/US2017/031352 patent/WO2017193030A1/en not_active Ceased
-
2020
- 2020-05-28 US US16/885,766 patent/US20210113532A1/en not_active Abandoned
-
2021
- 2021-04-13 JP JP2021067440A patent/JP2021107415A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515042A5 (https=) | ||
| JP2019519599A5 (https=) | ||
| JP2019515043A5 (https=) | ||
| JP2019530649A5 (https=) | ||
| RU2022106770A (ru) | Модуляторы интегрированного сигнального пути стресса | |
| HRP20210252T1 (hr) | Heterociklički amidi kao inhibitori kinaze | |
| AU765473B2 (en) | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | |
| CN114729044B (zh) | 毒蕈碱型乙酰胆碱m1受体拮抗剂 | |
| WO2015101928A1 (en) | Fused thiophene and thiazole derivatives as ror gamma modulators | |
| AU2019217320B2 (en) | Steroid derivative regulators, method for preparing the same, and uses thereof | |
| AU2020353663B2 (en) | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | |
| JP2019508407A5 (https=) | ||
| AU2004215481A1 (en) | Pyrazolo(1,5-A)pyrimidine derivatives | |
| JP2009534407A5 (https=) | ||
| HRP20161010T1 (hr) | C5ar antagonisti | |
| JP2021501781A5 (https=) | ||
| JP2017502088A5 (https=) | ||
| JP2009534406A5 (https=) | ||
| JP2017538712A5 (https=) | ||
| AU2019389017B2 (en) | Methods of treating disease with MAGL inhibitors | |
| CA3043612A1 (en) | Magl inhibitors | |
| HRP20230518T1 (hr) | Heteroarilfenoksibenzamidni opioidni ligandi kapa | |
| JP2025509635A5 (https=) | ||
| RS50443B (sr) | Derivati aminotiazola i njihova primena kao liganada crf receptora | |
| TW200635589A (en) | Therapeutic agents |